References
- Carney G, Maclure M, Patrick DM, Fisher A, Stanley D, Bassett K, et al. A cluster randomized trial assessing the impact of personalized prescribing feedback on antibiotic prescribing for uncomplicated acute cystitis to family physicians. PLoS One. 2023;18(7):e0280096.
- Naber KG, Alidjanov JF, Blicharski T, Cerska M, Gadzinski W, Kawecki J, et al. Polish version of the acute cystitis symptom score for patients with acute uncomplicated cystitis. Cent European J Urol. 2023;76(2):144-54.
- Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: the current scenario and future prospects. Pathogens. 2023;12(4):623.
- Kuiper SG, Dijkmans AC, Wilms EB, Kamerling IMC, Burggraaf J, Stevens J, et al. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection. J Antimicrob Chemother. 2020;75(11):3278-85.
- Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women – a systematic review and meta-analysis. J Chemother. 2022;34(3):139-48.
- Wang T, Wu G, Wang J, Cui Y, Ma J, Zhu Z, et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(1):106018.
- Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016:2082693.
- Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7(2):a025262.
- Ito R, Mustapha MM, Tomich AD, Callaghan JD, McElheny CL, Mettus RT, et al. Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene. mBio. 2017;8:e00749-17.
- Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-50.
- Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18.
- EUCAST Clinical Breakpoints Tables v. 13.1, valid from 2023-06-29. [https://www.eucast.org/clinical_breakpoints]
- Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10(2):165.
- European Committee on Antimicrobial Susceptibility Testing. 2020. EUCAST fosfomycin consultation document.
- [ https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/2020/EUCAST_General_Consultation_on_Fosfomycon_trometamol_2020.pdf]
- Giske CG, Turnidge J, Cantón R, Kahlmeter G. EUCAST steering committee. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2022;60(3):e0027621.
- Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol. 2019;68(4):403-15.
- López-Sampedro I, Hernández-Chico I, Gómez-Vicente E, Expósito-Ruiz M, Navarro-Marí JM, Gutiérrez-Fernández J. Evolution of antibiotic resistance in Escherichia coli and Klebsiella pneumoniae from urine cultures. Arch Esp Urol. 2023;76(3):203-14.
- Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Mouton JW, Peleg AY. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. J Microbiol Methods. 2020;171:105861.
- Wijma RA, Huttner A, van Dun S, Kloezen W, Abbott IJ, Muller AE, et al. Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers. Int J Antimicrob Agents. 2019;54(4):435-41.
- Portillo-Calderón I, Ortiz-Padilla M, Rodríguez-Martínez JM, de Gregorio-Iaria B, Blázquez J, Rodríguez-Baño J, et al. Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. J Antimicrob Chemother. 2020;75(8):2066-75.